Logo

ADVB

Advanced Biomed Inc. Common Stock

ADVB

Advanced Biomed Inc. Common Stock • NASDAQ
$0.42 ▲ 1.16% (+0.00)
Market Cap $9.09 M
52w High $4.10
52w Low $0.34
Dividend Yield 0%
P/E -2.47
Volume 153.00K
Outstanding Shares 21.64M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $0 ▼ $523.914K ▲ $-12.925K ▲ 0% ▲ $-0.001 ▲ $-11.325K ▲
Q4-2025 $17.2K ▲ $37.215K ▲ $-22.741K ▲ -132.215% ▼ $-0.001 ▲ $-20.657K ▲
Q3-2025 $0 $20.814K ▲ $-1.384M ▼ 0% $-0.069 ▼ $-684.6K ▼
Q2-2025 $0 $13.193K ▲ $-907.904K ▼ 0% $-0.045 ▼ $-426.658K ▼
Q1-2025 $0 $12.926K $-265.58K 0% $-0.013 $-417.809K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $2.657M ▲ $6.243M ▲ $3.239M ▲ $3.004M ▲
Q4-2025 $99.408K ▼ $222.933K ▼ $103.888K ▼ $119.045K ▼
Q3-2025 $156.135K ▼ $8.288M ▲ $4.158M ▲ $4.13M ▲
Q2-2025 $2.657M ▲ $4.504M ▲ $3.885M ▲ $619.032K ▼
Q1-2025 $2.647M $4.474M $3.38M $1.094M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $-386.901K ▼ $-20.39K ▲ $-59.167 ▲ $14.949K ▲ $-12.247K ▲ $-20.45K ▲
Q4-2025 $-22.741K ▲ $-58.648K ▲ $-676 ▲ $-11.347K ▼ $-56.727K ▼ $-59.32K ▲
Q3-2025 $-42.075K ▲ $-3.41M ▼ $-2.215K ▼ $5.899M ▲ $2.527M ▲ $-103.27K ▲
Q2-2025 $-907.904K ▼ $-841.841K ▼ $10.692K ▲ $408.286K ▲ $10.243K ▼ $-831.149K ▼
Q1-2025 $-265.58K $-29.68K $-19.978K $392.525K $39.019K $-49.658K

Five-Year Company Overview

Income Statement

Income Statement The income statement shows a very early‑stage profile. There is effectively no reported revenue yet, which means the company has not proven its commercial model in public filings. Past earnings per share have been negative, consistent with a business that is likely spending on development and overhead without sales to offset those costs. Overall, the income statement points to a pre‑revenue, loss‑making company with results that may remain volatile and hard to predict until it begins to generate meaningful revenue.

Balance Sheet

Balance Sheet The balance sheet is small and simple. The company reports a modest base of total assets with a meaningful portion in cash, no reported debt, and positive equity. That combination suggests a clean capital structure and some financial flexibility, but also limited resources compared with larger healthcare peers. The company may have room to fund near‑term operations, yet longer‑term activities will likely depend on its ability to raise additional capital or move products toward commercialization.

Cash Flow

Cash Flow Cash‑flow data are essentially unavailable in the provided information, which makes it difficult to judge how quickly the company is using cash or how efficiently it is spending. Given the lack of revenue and the early stage of development, it is reasonable to assume operating cash flow is negative and funded by equity rather than by the business itself. The main cash‑flow question going forward is how long current resources can support operations before new funding is needed.

Competitive Edge

Competitive Edge Within the medical diagnostics and research space, Advanced Biomed appears to be a very small and emerging player. The industry is dominated by large, well‑funded companies with established products, global sales channels, and deep regulatory experience. A young, pre‑revenue company typically competes by focusing on a narrow set of technologies or unmet medical needs rather than scale. Until more detail is available on its specific products, partnerships, and trial results, its competitive strength versus larger diagnostics firms remains highly uncertain.

Innovation and R&D

Innovation and R&D Public information on Advanced Biomed’s specific technologies, product pipeline, and research programs is very limited. This makes it hard to assess how differentiated its science is, where it stands in clinical or regulatory pathways, or how defensible its intellectual property might be. For a company in diagnostics and research, long‑term value will hinge on the quality of its underlying technology, the strength of its patents, and its ability to translate laboratory progress into approved, clinically adopted solutions. Those factors are not yet clear from current disclosures.

Summary

Overall, Advanced Biomed looks like a very early‑stage, pre‑revenue healthcare company with a clean but small balance sheet and limited public detail on its pipeline. The business is likely focused on development rather than commercialization, with ongoing losses and negative cash generation typical for this phase. Its future will depend heavily on scientific and regulatory milestones, the ability to raise capital as needed, and ultimately its success in carving out a niche in a highly competitive diagnostics landscape. The current data set is thin, so any interpretation carries a high degree of uncertainty until more robust financial and operational disclosures become available.

NEWS

September 19, 2025 · 8:30 AM UTC

Advanced Biomed Inc. Announces Launch of A+PerfusC™ – Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery

Read more